Summary:
Do you have lupus?
Do you currently have symptoms?
Would you be interested in helping us research an investigational drug?
We are currently recruiting patients into the ADDRESS II Study which is looking at an investigational drug for lupus (systemic lupus erythematosus, SLE). The investigational drug is being given in addition to other medications for lupus and acts on certain cells in the immune system known as B cells, which are believed to play an important role in lupus.
You may be eligible to take part in the ADDRESS II Study if you:
- are 18 years of age or older
- have had lupus for 6 months or more
- have active lupus at the time you participate in the study
This lupus research study will last for about 1 year, which includes 24 weeks of dosing with the study drug, and about 15 study center visits. If you are able to take part, you will be monitored carefully by a team of experienced medical personnel. Study drugs, exams, and study-related care will be provided at no cost to you, and you may be reimbursed for certain expenses, such as traveling and parking. At the end of the ADDRESS II Study dosing period, study participants will be given the option of participating in a research study extension, which would mean further continuing the investigational drug for up to 2 years.